natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the pigment of the absorptive layer has a BET specific surface area of greater than 25 m2/g, a d50 value from 0.3 to 3 μm and a porosity, when in form of a compacted bed, of greater or equal to 35%. 
Tiskovna podloga prema zahtjevu 3, pri čemu pigment ima specifičnu površinu veću od 25 m2/g, d50 vrijednost od 0.3 do 3 µm i poroznost, kada je u kompaktnom obliku, veću ili jednaku 35 %.
comprises within its N-terminal region (preferably within its 300 N-terminal amino-acids, more preferably within its 250 N-terminal aminoacids, and still more preferably within its 200 N-terminal aminoacids), a domain having at least 40%, and by order of increasing preference, at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 98% sequence identity, or at least 60%, and by order of increasing preference, at least, 65, 70, 75, 80, 85, 90, 95 or 98% sequence similarity with the FHA domain of the AtPS1 protein (amino acids 64-132 of SEQ ID NO: 1); 
u svom N-terminalnom segmentu (po mogućnosti unutar njegovih 300 N-terminalnih aminokiselina a još je poželjnije da to bude unutar njegovih 250 N-terminalnih aminokiselina ili još poželjnije unutar njegovih 200 N-terminalnih aminokiselina), sadrži jednu domenu čija je identičnost sekvenci s FHA domenom proteina AtPS1 (aminokiseline 64-132 identifikacijskog broja sekvence SEQ ID NO: 1) najmanje 40% odnosno, redom rastuće poželjnosti, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% ili 98%, ili čija je sličnost sekvenci s FHA domenom proteina AtPS1 najmanje 60% odnosno, redom rastuće poželjnosti, najmanje 65%, 70%, 75%, 80%, 85%, 90%, 95% ili 98%;
comprises within its C-terminal region (preferably within its 350 N-terminal aminoacids, more preferably within its 300 N-terminal aminoacids, and still more preferably within its 250 N-terminal aminoacids), a domain having at least 40%, and by order of increasing preference, at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 98% sequence identity, or at least 60%, and by order of increasing preference, at least, 65, 70, 75, 80, 85, 90, 95 or 98% sequence similarity with the PINc domain of the AtPS1 protein (amino acids 1237-1389 of SEQ ID NO: 1). 
u svom C-terminalnom segmentu (po mogućnosti unutar njegovih 350 C-terminalnih aminokiselina a još je poželjnije da to bude unutar njegovih 300 C-terminalnih aminokiselina ili još poželjnije unutar njegovih 250 C-terminalnih aminokiselina), sadrži jednu domenu čija je identičnost sekvenci s PINc domenom proteina AtPS1 (aminokiseline 1237-1389 identifikacijskog broja sekvence SEQ ID NO: 1) najmanje 40% odnosno, redom rastuće poželjnosti, najmanje 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% ili 98%, ili čija je sličnost sekvenci s tom PINc domenom proteina AtPS1 najmanje 60% odnosno, redom rastuće poželjnosti najmanje, 65%, 70%, 75%, 80%, 85%, 90%, 95% ili 98%;
A method according to claim 1, wherein the inhibition of said protein is obtained by expressing in said plant of a silencing RNA targeting the gene encoding said protein. 
Metoda prema zahtjevu 1, naznačena time da se inhibicija spomenutog proteina postiže ekspresijom stišavajuće ribonukleinske kiseline u spomenutoj biljci, pri čemu se cilja na genetsko kodiranje spomenutog proteina.
a DNA construct selected among: a DNA construct of 200 to 1000 bp, preferably of 300 to 900 bp, comprising a fragment of a cDNA encoding a PS1 protein or of its complementary, or having at least 95% identity, and by order of increasing preference, at least 96%, 97%, 98%, or 99 % identity with said fragment 
neki DNK konstrukt odabran između DNK konstrukta od 200 do 1000 bp, po mogućnosti od 300 do 900 bp, koji sadrži jedan fragment cDNK koji kodira protein PS1 ili njegov komplementarni protein ili čija je identičnost sa spomenutim fragmentom najmanje 95% odnosno, redom rastuće poželjnosti najmanje 96%, 97%, 98%, ili 99 %;
A transgenic plant producing 2n pollen, wherein said plant contains a transgene comprising an expression cassette of claim 4. 
Transgenska biljka koja proizvodi pelud 2n, naznačena time da ta biljka sadrži jedan transgen koji sadrži kazetu za ekspresiju iz zahtjeva 4.
the polyalkyleneimine is hydrophobically modified by replacement of all or part of the hydrogens of their primary and/or secondary amino groups by functional group R, where R comprises a linear or branched or cyclic alkyl and/or aryl group and contains 1 to 32 carbon atoms; 
polialkilenimin se hidrofobno modificira tako da se na svim ili nekim vodicima zamijene njihove primarne i/ili sekundarne amino skupine s funkcionalnom skupinom R, gdje R obuhvaća linearni ili razgranati ili ciklički alkil i/ili arilnu skupinu i sadrži 1 do 32 atoma ugljika;
passing a gas through the suspension of step c); 
prolaz plina kroz suspenziju iz koraka c);
Process according to claim 1, characterised in that said alkaline earth metal carbonate of step a) is a calcium and/or magnesium carbonate, and is more preferably a calcium carbonate such as marble or dolomite containing calcium carbonate. 
Proces prema zahtjevu 1, naznačen time što je karbonat alkalijskog zemnog metala iz koraka a) kalcijev i/ili magnezijev karbonat, i poželjnije kalcijev karbonat kao što je mramor ili dolomit koji sadrže kalcijev karbonat.
Process according to any of claims 1 to 3, characterised in that the weight ratio of said alkaline earth metal carbonate(s): silicate(s) in the mineral material of step a) is from 0.1:99.9 to 99.9:0.1, and preferably from 80:20 to 99:1. 
Proces prema bilo kojem od zahtjeva 1 do 3, naznačen time što je težinski omjer tog karbonata alkalijskog zemnog metala prema silikatu u mineralnom materijalu iz koraka a) od 0.1:99.9 do 99.9:0.1, i poželjno od 80:20 do 99:1.
Process according to any of claims 1 to 4, characterised in that the total of said alkaline earth metal carbonates and said silicates accounts for at least 95 %, preferably 98 %, by weight relative to the total weight of said mineral material. 
Proces prema bilo kojem od zahtjeva 1 do 4, naznačen time što ukupno taj karbonat alkalijskog zemnog metala i silikati čine najmanje 95%, poželjno 98% težine u odnosu na ukupnu težinu tog mineralnog materijala.
Process according to any of the claims 1 to 6, characterised in that said mineral material comprises a non-ionic or cationic grinding aid. 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time što taj mineralni materijal sadrži ne-ionsko ili kationsko pomoćno sredstvo za usitnjavanje.
Process according to any of claims 1 to 11, characterised in that said R functional group(s) of said hydrophobically modified polyalkyleneimine comprise oxygen, carboxyl, hydroxyl and/or nitrogen groups. 
Proces prema bilo kojem od zahtjeva 1 do 11, naznačen time što R funkcionalna skupina(e) tog hidrofobno modificiranog polialkilenimin sadrži kisikove, karboksilne, hidroksilne i/ili dušične skupine.
Process according to any of claims 1 to 12, characterised in that said R functional group(s) of said hydrophobically modified polyalkyleneimine are selected from the group consisting of linear or branched fatty amides or amines, cyclic amides or amines, and mixture thereof, and more preferably is a linear or branched fatty amide, a cyclic amide or a mixture thereof. 
Proces prema bilo kojem od zahtjeva 1 do 12, naznačen time što se R funkcionalna skupina(e) tog hidrofobno modificiranog polialkilenimin izabire iz grupe koja obuhvaća linearne ili razgranate masne amide ili amine, cikličke amide ili amine, i njihove mješavine, i poželjnije je to linearni ili razgranati masni amid, ciklički amid ili njihove mješavine.
Process according to any of claims 1 to 15, characterised in that said hydrophobically modified polyalkyleneimine is added in an amount of from 5 to 50 mg of said hydrophobically modified polyalkyleneimine/m2, preferably of from 10 to 45 mg of said hydrophobically modified polyalkyleneimine/m2 of silicate in said mineral material of step a). 
Proces prema bilo kojem od zahtjeva 1 do 15, naznačen time što se hidrofobno modificirani polialkilenimin dodaje u količini od 5 do 50 mg tog hidrofobno modificiranog polialkilenimina/m2, poželjno od 10 do 45 mg tog hidrofobno modificiranog polialkilenimina/m2 silikata u mineralnom materijalu iz koraka a).
Process according to any of claims 21 to 23, characterised in that step f) is followed by step h), which takes place before, during or after any step g), of concentrating the liquid fraction of step f) mechanically and/or thermally. 
Proces prema bilo kojem od zahtjeva 21 do 23, naznačen time što nakon koraka f) slijedi korak h), koji se odvija prije, tijekom ili nakon bilo kojeg koraka g), a u kojem se koncentrira tekuća frakcija iz koraka f) mehanički i/ili termalno.
Process according to claim 23, characterised in that a hydrophobically modified polyalkyleneimine recovered in step g) is implemented as the hydrophobically modified polyalkyleneimine of step b), said recovered hydrophobically modified polyalkyleneimine being preferably implemented in an amount accounting for at least 30 %, preferably at least 50 %, and more preferably at least 66 % by weight of said hydrophobically modified polyalkyleneimine of step b). 
Proces prema zahtjevu 23, naznačen time što se hidrofobno modificirani polialkilenimin dobiven u koraku g) implementira kao hidrofobno modificirani polialkilenimin iz koraka b), taj dobiveni hidrofobno modificirani polialkilenimin poželjno se implementira u količini koja predstavlja barem 30%, poželjno barem 50%, i najpoželjnije barem 66% tog hidrofobno modificiranog polialkilenimina iz koraka b).
A lice comb according to claim 1, characterized in that the material of the teeth of the lice comb means (4) is chosen from between fibre optics or some type of polyethylene material having good light conductivity. 
Češalj za uši prema 1. zahtjevu, naznačen time što se materijal zubaca sredstva češlja za uši (4) bira od optičkih vlakana ili neke vrste polietilenskog materijala dobre svjetlosne provodljivosti.
A lice comb according to claims 1 and 2, characterized in that the said body or handle (2) also supports a curved bristle brush (3) embedded in a position on its side surface, suitable for cleaning the teeth (4) of the lice comb means. 
Češalj za uši prema 1. i 2. zahtjevu, naznačen time što navedeno tijelo ili drška (2) drži i zakrivljenu četku (3) uležištenu njenim bočnim dijelom, prikladnu za čišćenje zubaca (4) sredstva češlja za uši.
The DNA polymerase chimera according to claim 2, wherein the amino acid sequence of (c) comprises at least one HhH domain derived from the topoisomerase V of Methanopyrus kandleri. 
DNK polimeraza himera prema zahtjevu 2, gdje lanac amino kiselina sadrži najmanje jednu HhH domenu izvedenu iz topizomeraze V od Methanopyrus kandleri.
The DNA polymerase chimera according to claim 3, wherein the amino acid sequence of (c) is SEQ ID NO: 3. 
DNK polimeraza himera prema zahtjevu 3, gdje je lanac amino kiseline od © SEQ ID NO: 3.
The DNA polymerase chimera according to any of claims 1 to 5, wherein the connecting amino acid sequence of (b) is SEQ ID NO: 5 or SEQ ID NO: 6. 
DNK polimeraza himera prema bilo kojem zahtjevu od 1 do 5, gdje je spojni lanac amino kiseline od (b) SEQ ID NO: 5 ili SEQ ID NO: 6.
The DNA polymerase chimera according to any of claims 1 to 7, wherein the φ29 type DNA polymerase of (a) has an amino acid sequence having an identity of at least 80% with SEQ ID NO: 1. 
DNK polimeraza himera prema bilo kojem zahtjevu od 1 do 7, gdje φ29 tip DNK polimeraza od (a) ima jedan lanac amino kesline koji je identičan najmanje 80% sa SEQ ID NO: 1.
The DNA polymerase chimera according to any of claims 1 to 9, wherein the φ29 type DNA polymerase of (a) has a modification in the exonuclease domain and wherein said modified DNA polymerase has less than 10% of exonuclease activity than the corresponding naturally occurring DNA polymerase. 
DNK polimeraza himera prema bilo kojem zahtjevu od 1 do 9, gdje φ29 tip DNK polimeraza od (a) ima modifikaciju u eksonukleaznoj domeni i gdje navedena modificirana DNK polimeraza ima manje od 1% eksonukleaznog djelovanja od odgovarajućeg djelovanja koje se prirodno pojavljuje u DNK polimerazi.
The DNA polymerase chimera according to claim 10, wherein the modified φ29 type DNA polymerase of (a) has less than 1% of exonuclease activity than the corresponding naturally occurring DNA polymerase. 
DNK polimeraza himera prema zahtjevu 10, gdje modificiran φ29 tip DNK polimeraza od (a) ima manje od 1% of eksonukleaznog djelovanja od odgovarajuće DNK polimeraze koja se pojavljuje prirodno.
Method for replicating, amplifying or sequencing a template DNA which comprises contacting said DNA with a reaction mixture comprising at least: the DNA polymerase chimera according to any of claims 1 to 11, a buffer, 
Metoda za repliciranje, amplifikaciju ili sekvenciranje predloška DNK koji sadrži spomenuti povezni DNK s reakcijskom smjesom koja sadrži najmanje: a) DNK polimerazu himera prema bilo kojem zahtjevu od 1 do 11, b) pufer, c) magnezijev klorid, d) početnicu, i nukleozidne trifosfate.
The method according to claim 17, wherein the potassium salt is potassium chloride or potassium acetate. 
Metoda prema zahtjevu 17, gdje je kalijeva sol kalijev klorid ili kalijev acetat.
The method according to claim 20, wherein the ammonium salt is ammonium sulfate. 
Metoda prema zahtjevu 20, gdje je amonijeva sol amonijev sulfat.
The method according to claim 20, wherein the ammonium salt is ammonium chloride or ammonium acetate. 
Metoda prema zahtjevu 20, gdje je amonijeva sol amonijev klorid ili amonijev acetat.
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, or R7 and R5 together with the corresponding N atom and C atom to which they are attached may form a substituted or unsubstituted heterocyclic group; 
se bira između vodika, CORa, COORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila, ili R7 i R5 skupa sa odgovarajućim N atomom i C atomom za koje su pričvršćeni mogu da formiraju supstituiranu ili nesupstituiranu heterocikličnu grupu;
A compound according to any of claims 1 to 11, wherein W is NR7 and wherein R7 and R5 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted pyrrolidine group. 
Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, što je W NR7 i gdje R7 i R5 skupa sa odgovarajućim N atomom i C atomom za koje su prikačeni formiraju supstituiranu ili nesupstituiranu pirolidinsku grupu.
A pharmaceutical composition comprising a compound according to any preceding claim, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutska smjesa, naznačena time, što sadrži spoj prema bilo kojem od prethodnih zahtjeva, ili farmaceutski prihvatljivu sol, tautomer ili stereoizomer istoga, i farmaceutski prihvatljivi razblaživač ili nosač.
Use of a compound according to any of claims 1 to 20, or pharmaceutically acceptable salts, tautomers or stereoisomers thereof, in the preparation of a medicament for the treatment of cancer. 
Upotreba spojeva ili smijese prema bilo kojem od zahtjeva 1 do 19, ili farmaceutski prihvatljive soli, tautomera ili stereoizomera istoga, naznačena time, što se koristi za izradu lijeka za liječenje kancera.
A system (100) for providing CAMEL roaming services to a mobile subscriber device (110) subscribed to a home network operator, operating in a home CAMEL phase, to avail one or more mobile services from a visited network operator, operating in a visited CAMEL phase, said system comprising: 
Sustav (100) za pružanje CAMEL roaming usluga mobilnom pretplatničkom uređaju (110) pretplaćenom na operatora kućne mreže, koji djeluje u kućnoj CAMEL fazi, da bi se koristila jedna ili više mobilnih usluga posjećenog mrežnog operatera, koji djeluje u posjećenoj CAMEL fazi, koji sustav uključuje:
receive a first request from the mobile subscriber device (110) through the visited network operator, the first request being compatible with visited CAMEL phase; 
prima prvi zahtjev mobilnog pretplatničkog uređaja (110) putem posjećenog mrežnog operatera, koji prvi zahtjev je kompatibilan sa posjećenom CAMEL fazom;
convert the first request to a second request, the second request being compatible with the home CAMEL phase; 
pretvara prvi zahtjev u drugi zahtjev, koji drugi zahtjev je kompatibilan sa kućnom CAMEL fazom;
send the second request to a home location register associated with the home network, operating in home CAMEL phase; and allow the mobile subscriber device (110) to avail the one or more mobile services seamlessly from the visited network operator independent of the visited CAMEL phase, the home CAMEL phase being different from the visited CAMEL phase. 
šalje drugi zahtjev kućnom registru lokacije povezanim sa kućnom mrežom, koja djeluje u kućnoj CAMEL fazi; i dopušta mobilnom pretplatničkom uređaju (110) da koristi jednu ili više mobilnih usluga bez diskontinuiteta od posjećenog mrežnog operatera neovisno od posjećene CAMEL faze, koja kućna CAMEL faza je drugačija od posjećene CAMEL faze.
The system (100) as claimed in claim 1, wherein the first request is a request to update location of the mobile subscriber from a visitor location register associated with the visited network operator. 
Sustav (100) temeljem zahtjeva 1, naznačen time što je prvi zahtjev zahtjev za ažuriranje lokacije mobilnog pretplatnika od strane posjećenog registra lokacija povezanog sa posjećenim mrežnim operaterom.
The system (100) as claimed in claim 8, wherein the CAMEL HUB (112) is further configured to: 
Sustav (100) temeljem zahtjeva 8, naznačen timešto je CAMEL ČVORIŠTE (112) dalje konfigurirano da:
receive first Insert Subscriber Data and CAMEL subscription information from the home location register in response to the second request, the first Insert Subscriber Data being compatible with home CAMEL phase; 
prima prve Umetnute pretplatničke podatke i CAMEL podatke o pretplati od kućnog registra lokacija kao odgovor na drugi zahtjev, koji prvi Umetnuti pretplatnički podaci su kompatibilni sa kućnom CAMEL fazom;
The system (100) as claimed in claim 4, wherein the portion of CAMEL subscription information corresponds to originating CAMEL subscription information. 
Sustav (100) temeljem zahtjeva 4, naznačen timešto dio CAMEL pretplatničkih podataka odgovara izvornim CAMEL pretplatničkim podacima.
The system (100) as claimed in claim 4, wherein the CAMEL HUB (112) is further configured to store the short message service CAMEL subscription information. 
Sustav (100) temeljem zahtjeva 4, naznačen timešto je CAMEL ČVORIŠTE (112) dalje konfigurirano da pohranjuje CAMEL pretplatničke podatke SMS usluge.
receive first insert subscriber data and a General Packet Radio Service CAMEL subscription information from the home location register in response to the second request, the first subscriber data being compatible with home CAMEL phase; 
prima prve umetnute korisničke podatke i GPRS CAMEL pretplatničke podatke od kućnog registra lokacija kao odgovor na drugi zahtjev, gdje su prvi pretplatnički podaci kompatibilni sa kućnom CAMEL fazom;
The system (100) as claimed in claim 8, wherein the CAMEL HUB (112) is further configured to: 
Sustav (100) temeljem zahtjeva 9, naznačen timešto je CAMEL ČVORIŠTE (112) dalje konfigurirano da pohranjuje GPRS CAMEL pretplatničke podatke.
The system (100) as claimed in claim 1, wherein a phase relationship between the home network operator and the visited network operator is determined; and the received request message is modified based at least in part on the phase relationship. 
Sustav (100) temeljem zahtjeva 1, naznačen timešto je fazni odnos između kućnog mrežnog operatera i posjećenog mrežnog operatora određen; i primljena poruka sa zahtjevom je modificirana barem dijelom na temelju faznog odnosa.
The system (100) as claimed in claim 12, wherein the message corresponds to one of mobile application part message or CAMEL message. 
Sustav (100) temeljem zahtjeva 12, naznačen timešto poruka odgovara poruci dijela mobilne aplikacije ili CAMEL poruci.
A compound as claimed in claim 1 selected from the group consisting of: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine koja sadrži:
The pharmaceutical composition as claimed in claim 6 which is adapted for administration by inhalation via the nose or mouth. 
Farmaceutski pripravak prema zahtjevu 6 naznačen time da je prilagođen za davanje inhalacijom kroz nos ili usta.
A compound as claimed in claim 8 or 9, wherein the respiratory disease is selected from asthma, chronic obstructive pulmonary disease (COPD), allergic airway syndrome, bronchitis, cystic fibrosis and emphysema. 
Spoj prema zahtjevu 8 ili 9, naznačen time da je respiratorna bolest odabrana od astme, kronične opstruktivne plućne bolesti (KOPB), alergijskog sindroma dišnih putova, bronhitisa, cistične fibroze i emfizema.
Process according to claim 21 or 22, characterised in that in step g) the liquid fraction of step f) is treated with an acid to reduce the pH of this liquid fraction by at least 1 pH unit. 
Proces prema zahtjevu 21 ili 22, naznačen time što se u koraku g) tekuća frakcija iz koraka f) obrađuje kiselinom radi snižavanja pH te tekuće frakcije za barem 1 pH jedinicu.
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl, with the proviso that when Y is-CHRay-CHRby-CHRcy- or -CHRay-CRby=CRcy- and a single or a double bond exists between the C atoms to which R3 and R4 are attached then R9 is substituted or unsubstituted C4-C12 alkenynyl; 
R3 i R4 su odsutni; se bira između vodika, CORa, COORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila, i supstituiranog ili nesupstituiranog C4-C12 alkeninila, uz uvjet da kada je Y - CHRay-CHRby-CHRCy- ili -CHRay-CRby=CRCy- i postoji jednoguba ili dvoguba veza između C atoma za koje su prikačeni R3 i R4, onda je R9 supstituirani ili nesupstituiraniC4-C12 alkeninil;
Use of a compound or composition according to any of claims 1 to 20, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, in the manufacture of a medicament for the treatment of cancer. 
Upotreba spojeva ili smijese prema bilo kojem od zahtjeva 1 do 19, ili farmaceutski prihvatljive soli, tautomera ili stereoizomera istoga, naznačena time, što se koristi za izradu lijeka za liječenje kancera.
Rod pumping system comprising one or more well tubings and sucker rods disposed in each of the well tubings, the well tubing comprising a plurality of tubing sections each having a bore and an inside diameter, wherein at least part of the tubing sections has polymer liners disposed within said bore of said tubing section, characterized in that said polymer liners are comprised of crosslinked polyethylene, wherein each of the sucker rods comprises a plurality of rod sections, individual rod sections being connected to each other by couplings, and wherein the couplings have a surface roughness Ra of ≤ 2.8 µm and a surface hardness HV200 of ≥ 300. 
Sustav crpljenja sa šipkom koji se sastoji od jedne ili više cijevi bušotine i klipnih šipki koje su postavljene u svaku cijev bušotine, pri čemu se cijev bušotine sastoji od većeg broja dijelova cijevi koje svaka imaju šupljinu i unutrašnji promjer, gdje barem dio dijelova cijevi ima polimerne obloge koje su položene unutar navedene šupljine spomenutog dijela cijevi, naznačen time da se navedene polimerne obloge sastoje od umreženog polietilena, pri čemu se svaka klipna šipka sastoji od većeg broja dijelova šipki, a pojedinačni dijelovi šipki su međusobno spojeni spojkama, te pri čemu spojke imaju površinsku hrapavost od Ra ≤ 2.8 um i površinsku tvrdoću od HV200 ≥ 300.
Rod pumping system according to claim 1, characterized in that the liners have a thickness of 0.5 - 10 mm. 
Sustav crpljenja sa šipkom prema zahtjevu 1, naznačen time da obloge imaju debljinu od 0.5 - 10 mm.